Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics Inc (NQ: VRDN )

13.81 +0.55 (+4.15%)
Official Closing Price Updated: 4:15 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,018,259
Open 13.31
Bid (Size) 13.05 (1)
Ask (Size) 14.67 (1)
Prev. Close 13.26
Today's Range 13.31 - 14.40
52wk Range 10.93 - 28.99
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire

Performance

YTD
-38.21%
-38.21%
1 Month
-19.99%
-19.99%
3 Month
-29.32%
-29.32%
6 Month
+10.39%
+10.39%
1 Year
-51.78%
-51.78%

More News

Read More
Unveiling 4 Analyst Insights On Viridian Therapeutics
Via Benzinga
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
Via InvestorPlace
Navigating 6 Analyst Ratings For Viridian Therapeutics
Via Benzinga
Analyst Ratings for Viridian Therapeutics
Via Benzinga
Where Viridian Therapeutics Stands With Analysts
Via Benzinga
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
Via Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
From Viridian Therapeutics, Inc.
Via Business Wire
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
From Viridian Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.